Open Access

A new treatment option in HFrEF: how can we incorporate SGLT2 inhibitors into clinical practice?

Event: ESC Congress 2021 - The Digital Experience
Topic: Chronic Heart Failure
Session type: Satellite Symposium
Sponsored by the Boehringer Ingelheim and Eli Lilly and Company Alliance
Date: 29 August 2021
Time: 09:00 - 09:30

Session

This content is currently on OPEN ACCESS

Sign in to view the resources

Related content

ESC Premium Access

Evolving role of SGLT2i in HFrEF management

3 December 2021

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

ESC Premium Access

Current controversies in antithrombotic therapy

3 December 2021

This platform is supported by

logo Novo Nordisk